TransMedics, Inc. Secures $36 Million Round of Financing Lead by Foundation Capital and Kleiner Perkins Caufield & Byers

ANDOVER, Mass., March 4 /PRNewswire/ -- TransMedics, Inc., a leading medical device company focusing on delivering the next standard of care for solid organ transplantation worldwide, announced today the closing of a $36 million financing round. The financing was lead by Foundation Capital and Kleiner Perkins Caufield & Byers (KPCB) and also included investments by Flagship Ventures and by several existing investors.

TransMedics is the maker of the Organ Care System (OCS™). The OCS™ is a breakthrough technology platform, which maintains donor organs in near-physiologic and functioning condition during transport for organ transplantation. The OCS™ has the potential to significantly improve post-transplant clinical outcomes and expand the number of transplant procedures performed annually based on its unique and proprietary capabilities to overcome the current challenges of cold storage approach to donor organs. The OCS™ platform has been recognized by the Cleveland Clinic Foundation as one of the Top 10 Medical Innovations for 2009, and by CNN as one of the Top 10 Healthcare Innovations of 2009. In addition, OCS™ technology was featured in the February, 2007 issue of National Geographic magazine in an article titled "Mending Broken Hearts." The article discussed the latest and most promising medical technologies to address the growing heart failure epidemic.

"We are excited at the high level of confidence our investors have in our transforming technology and market potential," said Dr. Waleed Hassanein, President and CEO of TransMedics, Inc. "This financing enables us, over the next two years, to expand our commercial presence into the US market with our heart OCS™ device and to globally launch the OCS™ lung device."

"All of us at Foundation are thrilled to be part of such a high quality company and investor syndicate. TransMedics' OCS™ system can positively impact the quality of life for thousands of people each year, and will fundamentally change the way society thinks about organ transplantation. We are proud to play a small role in their team's road to commercial success," said Mr. Adam Grosser, General Partner, Foundation Capital.

"The field of solid organ transplantation is undergoing revolutionary advances, and TransMedics is positioned to emerge as the world leader in the field. We at Kleiner Perkins are extremely motivated to invest in companies that matter, that improve peoples lives in a significant way -- TransMedics clearly meets that criteria," said Mr. Joe Lacob, Partner, KPCB.

About TransMedics, Inc.

TransMedics is a privately held medical technology company dedicated to extending the life saving benefits of organ transplantation to patients suffering from end-stage organ failure. Headquartered in Andover, Massachusetts, the company was founded in 1998 to address the unmet need for more and better organs for transplants. For more information, please visit www.TransMedics.com.

About Foundation Capital

Founded in 1995, Foundation Capital is a venture capital firm committed to supporting entrepreneurs and their companies, targeting innovative opportunities in cleantech, consumer Internet and infrastructure; telecommunications and networking; and enterprise software and on demand services. Foundation Capital funds total more than $2.4 billion. For more information, please visit www.foundationcapital.com.

About Kleiner Perkins Caufield & Byers

Since its founding in 1972, Kleiner Perkins Caufield & Byers has backed entrepreneurs in over 500 ventures, including AOL, Amazon.com, Citrix, Compaq Computer, Electronic Arts, Genentech, Genomic Health, Google, Intuit, Juniper Networks, Netscape, Lotus, Sun Microsystems, Symantec, Verisign and Xilinx. KPCB portfolio companies employ more than 250,000 people. More than 150 of the firm's portfolio companies have gone public. Many other ventures have achieved success through mergers and acquisitions. The firm has offices in Menlo Park, California; Beijing, China; and Shanghai, China. For additional information visit please visit www.kpcb.com.